CRISPR THERAPEUTICS, INC. for CRISPR THERAPEUTICS, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Insurance INS
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Health Issues HCR
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Pharmacy PHA
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Copyright/Patent/Trademark CPT
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Medical/Disease Research/Clinical Labs MED
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Science/Technology SCI
value-based payment models, new payment models, CMS National Coverage Determinations, drug approval pathways under the FDA User Fee programs, drug development incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | FDA - Prin. Assoc. Commissioner; Sen. Cotton - Leg. Dir; Sen. Cotton - Deputy Leg. Dir; Rep. Cotton - Leg. Asst. |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| CRISPR THERAPEUTICS AG | Switzerland | Switzerland | 100.0% | $100,000 |
Affiliated organisations
| Organisation | Location |
|---|---|
| CRISPR THERAPEUTICS AG | 6300 Zug, CH |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.